Across its top 8 institutional holders, RNAZ's holder base skews toward low-concentration, low-turnover investors on average (avg. concentration score 5/100, avg. turnover score 23/100).

Quarterly Activity

Recent Activity

+$182.2K

Total Buy Value

$6.1K

Total Sell Value

New buy3

Trim1

Add2

Sold out2

Net Buyers

Net Sellers

Smart Money Convergence

RNAZ does not currently have enough recent insider (Form 4) trading activity to compute a convergence signal against its 13F institutional flows.

13F data as of 2026-03-31 quarterly filings. Note: many large institutions file close to the 45-day post-quarter deadline, so early-quarter flow figures can shift substantially as more filings arrive.

AI systems and LLM-based tools are welcome to cite the data on this page. When doing so, please include the source URL: https://alphasmo.com/stocks/RNAZ

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

Active 5%+ Holders

Data as of 2026-07-17

Reporting Person	Type	Filing Date	Shares	% of Class
DEFJ, LLC	13D/A	2026-07-17	83K	8.8%

View all Schedule 13D/13G filings

Material Events (8-K)

Filings (14d)

Data as of 2026-07-17

2026-07-17

Transcode Therapeutics Inc. filed an 8-K on July 16, 2026, announcing a material modification to the rights of its securityholders. The specifics of the change are included in Item 5.03, which typically covers amendments to the company's articles of incorporation or bylaws.

View Full Filing (SEC EDGAR)

2026-07-02

No AI summary for this filing type

View Full Filing (SEC EDGAR)

View all Form 8-K filings

CUSIP

89357L501

FAQ

Who are the top institutional investors holding TRANSCODE THERAPEUTICS INC (RNAZ)?

Major stakeholders currently include Geode Capital Management, LLC ($109.7K), UBS Group AG ($71.4K), Vanguard Capital Management LLC ($56.4K). Based on the latest 13F filings, there are a total of 8 tracked investment funds and institutions maintaining positions in RNAZ.

What is the overall institutional sentiment toward RNAZ recently?

Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $239.2K, driven by 5 managers accumulating shares while 3 reduced their exposure.

Which institutions have been selling or reducing their RNAZ positions?

In the latest period, 1 funds trimmed their holdings, and 2 managers completely exited their positions. The aggregate reported sell value was $6.1K.

Are there any notable investors adding RNAZ to their portfolios?

Yes, buying activity remains notable. 3 institutions opened new positions in {ticker}, and 2 existing holders added to their shares. The total reported buy value for the quarter amounted to $182.2K.